Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam

The latest drug development news and highlights from our US FDA Performance Tracker. 

Keeping Track Feature image

New molecular entities (NMEs) finally got back into the approval action after a drought of more than a month, as the US FDA gave the nod to Sage Therapeutics Inc.'s Zulresso (brexanolone) and Jazz Pharmaceuticals PLC's Sunosi (solriamfetol) as the fourth and fifth novel approvals of 2019.

But the news for NMEs wasn't all good, as Sanofi andLexicon Pharmaceuticals Inc.'s type 1 diabetes drug Zynquista...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet